W A Wuillemin - JoVE Visualize

Showing results (61-70 of 75) with videos related to

Pageof 8

Sort By:

Vox Sanguinis|January 15, 2010

Fatal outcome of a hepatitis B virus transfusion-transmitted infectionC Niederhauser, T Weingand, D Candotti, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|April 9, 1999

Coagulation factors II, V, VII, and X, prothrombin gene 20210G-->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarctionM Redondo, H H Watzke, B Stucki, et al.

Blood|March 15, 1995

Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitorW A Wuillemin, M Minnema, J C Meijers, et al.

Thrombosis and Haemostasis|February 12, 1999

Performance of a new fibrin monomer assay to exclude deep vein thrombosis in symptomatic outpatientsC Caliezi, N Fünfsinn, T Mauron, et al.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 21, 2001

Rapid D-dimer testing and pre-test clinical probability in the exclusion of deep venous thrombosis in symptomatic outpatientsN Fünfsinn, C Caliezi, F D Biasiutti, et al.

Thrombosis Research|August 16, 2011

Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratoriesL M Asmis, L Alberio, A Angelillo-Scherrer, et al.

Blood|October 27, 1998

Activation of clotting factor XI without detectable contact activation in experimental human endotoxemiaM C Minnema, D Pajkrt, W A Wuillemin, et al.

Journal of Internal Medicine|March 25, 2005

Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvementP Chopard, J Dörffler-Melly, U Hess, et al.

Thrombosis and Haemostasis|November 15, 2013

Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE)M Nendaz, D Spirk, N Kucher, et al.

Xenotransplantation|February 24, 2001

Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation modelsP Fiorante, Y Banz, P J Mohacsi, et al.

Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:

Pageof 8

Vox Sanguinis|January 15, 2010

Fatal outcome of a hepatitis B virus transfusion-transmitted infectionC Niederhauser, T Weingand, D Candotti, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|April 9, 1999

Coagulation factors II, V, VII, and X, prothrombin gene 20210G-->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarctionM Redondo, H H Watzke, B Stucki, et al.

Blood|March 15, 1995

Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitorW A Wuillemin, M Minnema, J C Meijers, et al.

Thrombosis and Haemostasis|February 12, 1999

Performance of a new fibrin monomer assay to exclude deep vein thrombosis in symptomatic outpatientsC Caliezi, N Fünfsinn, T Mauron, et al.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 21, 2001

Rapid D-dimer testing and pre-test clinical probability in the exclusion of deep venous thrombosis in symptomatic outpatientsN Fünfsinn, C Caliezi, F D Biasiutti, et al.

Thrombosis Research|August 16, 2011

Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratoriesL M Asmis, L Alberio, A Angelillo-Scherrer, et al.

Blood|October 27, 1998

Activation of clotting factor XI without detectable contact activation in experimental human endotoxemiaM C Minnema, D Pajkrt, W A Wuillemin, et al.

Journal of Internal Medicine|March 25, 2005

Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvementP Chopard, J Dörffler-Melly, U Hess, et al.

Thrombosis and Haemostasis|November 15, 2013

Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE)M Nendaz, D Spirk, N Kucher, et al.

Xenotransplantation|February 24, 2001

Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation modelsP Fiorante, Y Banz, P J Mohacsi, et al.

Pageof 8